| Name | Creo Medical Group |
|---|---|
| Epic | CREO |
| Isin | GB00BZ1BLL44 |
| Industry | Medical Equipment and Services |
| Latest share price | 18.50p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £76.25 | Debt ratio | n/a |
| Shares in issue | 412.15 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -56.88 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -7 | 52-week high / low | 14.10p / 42.80p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Creo Medical Group |
|---|---|
| Address | Creo House, Unit 2 Beaufort Park, Beaufort Park Way, Chepstow, Wales, United Kingdom, NP16 5UH |
| Telephone | +44 (0) 1291 606005 |
| Website | http://creomedical.com/ |
| Director | Position |
|---|---|
| Mr Craig Jonathan Gulliford | CEO |
| Mr Richard John Rees | CFO |
| Mr David Gerard Woods | Executive Director |
| Mr Christopher Paul Hancock | Chief Technology Officer |
| Mr Charles Spicer | Non-Executive Chairman |
| Mr John Bradshaw | Independent Non-Executive Director |
| Mr Kevin Crofton | Independent Non-Executive Director |
| Mrs Ivonne Cantu | Independent Non-Executive Director |
| Mr Brent Boucher | Independent Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 26.2 | 27.6 | 27.25 |
| Investments and other non-current assets | 2.1 | 2.1 | 1.73 |
| Total non-current assets | 38.7 | 41.6 | 39.44 |
| Inventory / work in progress | 8.1 | 9.3 | 8.5 |
| Trade and other receivables | 11.3 | 11.3 | 9.13 |
| Cash and equivalents | 3 | 13.1 | 43.53 |
| Other current assets and asset held for resale | 15.5 | n/a | n/a |
| Total of all assets | 76.6 | 75.3 | 100.61 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 9.9 | 17.4 | 19.74 |
| Long term liabilities | 6.9 | 8.5 | 7.55 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 16.8 | 25.9 | 27.29 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 59.8 | 49.4 | 73.32 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.4 | 0.2 | 0.18 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -144.4 | -122.7 | -95.76 |
| Share premium account | 180.9 | 149.5 | 149.45 |
| Total equity | 59.8 | 49.4 | 73.32 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -24.8 | -30.7 | -29.91 |
| Pre-tax profit | -24.5 | -30.9 | -30.34 |